---
title: "Codexis (CDXS) Gets a Buy from Jefferies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281414667.md"
description: "Jefferies analyst assigned a Buy rating to Codexis today and set a price target of $3.50.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for Codexis with a $5.50 average price target."
datetime: "2026-04-01T18:35:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281414667.md)
  - [en](https://longbridge.com/en/news/281414667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281414667.md)
---

# Codexis (CDXS) Gets a Buy from Jefferies

Jefferies analyst assigned a Buy rating to Codexis today and set a price target of $3.50.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Codexis with a $5.50 average price target.

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [CDXS.US](https://longbridge.com/en/quote/CDXS.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)